<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103334</url>
  </required_header>
  <id_info>
    <org_study_id>L9-E-CJT-CM-131003</org_study_id>
    <nct_id>NCT03103334</nct_id>
  </id_info>
  <brief_title>A Bioavailability Study of Methotrexate 25 mg Administered by Needle Injection and a Pre Filled Needle-free Device in Healthy Volunteers.</brief_title>
  <official_title>A Single Center Single Dose Open-label Randomized Two Period Crossover Study to Determine the Bioavailability of Two Formulations of Methotrexate 25 mg Administered by Needle Injection and a Pre-filled Needle-free Device in at Least 48 Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crossject</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crossject</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to determine whether the test product, Methotrexate 40 mg/mL solution for&#xD;
      injection administered subcutaneously by the prefilled and needle-free delivery system&#xD;
      Zeneo®, and the reference product, Methotrexate Biodim® 25 mg/mL, solution for injection&#xD;
      administered subcutaneously by a conventional syringe with needle are bioequivalent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ABSTRACT Objective: Zeneo1 is a needle-free injection device. We performed a pharmacokinetic&#xD;
      study to investigate the bioequivalence of methotrexate administered subcutaneously using&#xD;
      either the needle-free injection device or a conventional needle and syringe.&#xD;
&#xD;
      Research design and methods: This was a single-dose, open-label, laboratory-blind, randomized&#xD;
      crossover study performed in adult healthy volunteers. Each participant received two&#xD;
      methotrexate injections (each 25mg), one via needle-free injection device and one via&#xD;
      conventional injection, with a 21-28 day wash-out interval between dosing. For each&#xD;
      participant, the administration site for both injections was either the abdomen or the thigh.&#xD;
&#xD;
      Main outcome measures: The primary pharmacokinetic outcome parameters were AUC(0-t) and Cmax.&#xD;
&#xD;
      Bioequivalence was assessed by standard criteria: whether 90% confidence intervals of&#xD;
      geometric mean ratios for the two administration methods were within 80-125%.&#xD;
&#xD;
      Results: Fifty-two individuals completed the study. Bioequivalence criteria were met for&#xD;
      AUC(0-t), for the overall analysis (both injection sites: 90% confidence interval:&#xD;
      99.4-103.1%), and for each injection site separately. Bioequivalence was similarly&#xD;
      demonstrated with AUC(0-1). Bioequivalence criteria for Cmax were fulfilled for abdominal&#xD;
      administration but not for the overall analysis. Injection via the needle- free injection&#xD;
      device was well tolerated.&#xD;
&#xD;
      Limitations: Limitations include conducting the study in healthy volunteers and the&#xD;
      relatively small subject number (albeit satisfactory for bioequivalence).&#xD;
&#xD;
      Conclusions: This study shows that methotrexate injection via needle-free injection device is&#xD;
      bioequivalent to a conventional needle and syringe in relation to AUC(0-t) and AUC(0-1).&#xD;
      Studies of needle-free injection device use in patients requiring methotrexate therapy are&#xD;
      planned.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax).</measure>
    <time_frame>serial pharmacokinetic plasma concentrations were drawn prior pre-dose and post-dose at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) time zero to time of the last quantifiable concentration (AUC(0-t)).</measure>
    <time_frame>serial pharmacokinetic plasma concentrations were drawn prior pre-dose and post-dose at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Experimental A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zeneo® - Methotrexate thigh to Methotrexate Biodim® thigh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate Biodim® thigh to Zeneo® - Methotrexate thigh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zeneo® - Methotrexate abdomen to Methotrexate Biodim® abdomen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate Biodim® abdomen to Zeneo® - Methotrexate abdomen</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Zeneo® - Methotrexate</intervention_name>
    <description>0.625 mL of methotrexate solution 40 mg/ML for subcutaneous injection with a prefilled and needle-free delivery system</description>
    <arm_group_label>Experimental A</arm_group_label>
    <arm_group_label>Experimental B</arm_group_label>
    <arm_group_label>Experimental C</arm_group_label>
    <arm_group_label>Experimental D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate Biodim®</intervention_name>
    <description>1 mL of methotrexate solution 25 mg/mL for subcutaneous injection with a conventional needle and syringe injection</description>
    <arm_group_label>Experimental A</arm_group_label>
    <arm_group_label>Experimental B</arm_group_label>
    <arm_group_label>Experimental C</arm_group_label>
    <arm_group_label>Experimental D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects&#xD;
&#xD;
          -  BMI between 18.5 and 30 kg/m2&#xD;
&#xD;
          -  Body mass &gt; 60 kg&#xD;
&#xD;
          -  Non-tobacco user&#xD;
&#xD;
          -  Written consent given for participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of clinically relevant oral, cardiovascular, hematologic, gastrointestinal,&#xD;
             hepatic, renal, endocrine, pulmonary, neurologic, psychiatric or skin disorder&#xD;
&#xD;
          -  Heavy alcohol consumption and regular exposure to drug of abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

